[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335720-105":59,"doc-detail-335720-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","ten-year-outcome-of-a-randomized-trial-cytoreduction-and-hipec-with-mitomycin-c-versus-oxaliplatin-for-appendiceal-neoplasm-with-peritoneal-dissemination","Ten-Year Outcome of a Randomized Trial: Cytoreduction and HIPEC with Mitomycin C Versus Oxaliplatin for Appendiceal Neoplasm with Peritoneal Dissemination","","Background: Appendiceal cancer is rare and has been difficult to study prospectively. This work updates the first prospective randomized trial with 10-year follow-up after initial results showed similar 3-year survival and minor hematologic toxicity with mitomycin C or oxaliplatin. Methods: Patients with mucinous appendiceal neoplasms and peritoneal dissemination received HIPEC for 120 minutes using oxaliplatin (200 mg/M2) or mitomycin C (40 mg), and overall and disease-free survival were compared at 10 years. Results: 121 patients were analyzed and long-term survival was similar between groups. Conclusions: Long-term efficacy of oxaliplatin and mitomycin C in HIPEC appears comparable after cytoreduction surgery.",{"@graph":69,"@context":119},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ten-year-outcome-of-a-randomized-trial-cytoreduction-and-hipec-with-mitomycin-c-versus-oxaliplatin-for-appendiceal-neoplasm-with-peritoneal-dissemination/335720/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ten-year-outcome-of-a-randomized-trial-cytoreduction-and-hipec-with-mitomycin-c-versus-oxaliplatin-for-appendiceal-neoplasm-with-peritoneal-dissemination/335720.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115],{"name":110,"@type":111,"acceptedAnswer":112},"What patient population and HIPEC regimen were studied in this 10-year follow-up trial?","Question",{"text":113,"@type":114},"The trial enrolled patients with mucinous appendiceal neoplasms and peritoneal dissemination. HIPEC was delivered for 120 minutes with either oxaliplatin (200 mg/M2) or mitomycin C (40 mg).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Were long-term efficacies of mitomycin C and oxaliplatin different?",{"text":118,"@type":114},"The study concludes that oxaliplatin and mitomycin C have similar long-term efficacy for HIPEC in this clinical setting, with most patients experiencing long-term survival after CRS and HIPEC.","https://schema.org",{"og:url":83,"og:type":121,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":123,"canonical":83},"index,follow",{"doc_id":125,"site_id":62},335720,1790334521,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":92,"user_avatar":130,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":136,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":67,"update_tm":140,"read_time":46,"preview_page_count":4},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Ann Surg Oncol (2025) 32:679–686  \n[https://doi.org/10.1245/s10434-024-16441-z](https://doi.org/10.1245/s10434-024-16441-z)  \nORIGINAL ARTICLE – PERITONEAL SURFACE MALIGNANCY  \nTen‑Year Outcome of a Randomized Trial: Cytoreduction and HIPEC with Mitomycin C Versus Oxaliplatin for Appendiceal Neoplasm with Peritoneal Dissemination  \nEdward A. Levine, MD1, Heidy Cos, MD1, Konstantinos I. Votanopoulos, MD, PhD1, Perry Shen, MD1, Greg Russell, MS2, Paul Mansfield, MD3, Keith Fournier, MD3, David Bartlett, MD4, and  \nJohn H. Stewart, MD, MBA1  \n1Section of Surgical Oncology, Department of General Surgery, Wake Forest Baptist Health, Winston-Salem, NC; 2Department of Biostatistics and Data Science, Wake Forest Baptist Health, Winston-Salem, NC; 3M.D. Anderson Cancer Center, Houston, TX; 4University of Pittsburgh, Pittsburgh, PA  \nABSTRACT  \nBackground. Appendiceal cancer is a rare disease that has proven difficult to study in prospectively. Our initial report of this trial showed minor hematologic toxicity with both mitomycin C and oxaliplatin and similar 3-year survival. We now report an update of the first prospective randomized trial for appendiceal cancer with 10-year follow up.  \nPatients and Methods. Patients with mucinous appendiceal neoplasms and evidence of peritoneal dissemination were enrolled in the Multicenter Randomized Trial to evaluating HIPEC for 120 min with oxaliplatin (200 mg/M2) or mitomycin C (40 mg) . Overall survival and disease-free survival were calculated at 10 years and compared between the groups.  \nResults. A total of 121 patients were included in the study. The patients were 57% female, with a mean age of 55.3 years (range 22–82 years) . The disease was low grade in 71% and high grade in 29% . The average peritoneal cancer index (PCI) score was 18 (SD 10) in the mitomycin C group and 17.9 (SD 9.4) in the oxaliplatin group (p = 0.94) . The 10-year survival rate was 56.2%(SE 7.2) with mitomycin Cand 47.5%(SE 8.4) with oxaliplatin, p = 0.83. The 10-year  \nPrior presentation: Society of Surgical Oncology meeting, March 2024.  \n© The Author(s) 2024  \nFirst Received: 21 June 2024  \nAccepted: 18 October 2024  \nPublished online: 12 November 2024  \nE. A. Levine, MD  \ne-mail: [elevine@wakehealth.edu](elevine@wakehealth.edu)  \nprogression-free survival rate in the mitomycin C group was 45.2%(SE 8.4) compared with 50.4%(SE 6.7) in theoxaliplatin group, p = 0.95. Median survival was 9.1 years after HIPEC with oxaliplatin, and median not reached for the mitomycin C group (> 5.6 years) .  \nConclusions. Oxaliplatin and mitomycin C have similar long-term efficacy for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with appendiceal neoplasms and peritoneal dissemination. Long-term survival is experienced by most patients after cytoreduction surgery (CRS) and HIPEC for appendiceal neoplasms.  \nKeywords Appendiceal cancer · Pseudomyxoma · Chemotherapy · Oxaliplatin · Mitomycin C · HIPEC  \nAppendiceal mucinous neoplasms are rare, and without established screening systems, frequently present with peritoneal dissemination.1–5 There is great variability in the observed outcomes based on histologic type, tumor grade, and disease volume, with the best survival benefit observed in peritoneal surface disease (PSD) from low-grade appendiceal (LGA) primary lesions. However, even within the LGA group, there is significant variability, thus all appendiceal cancer is not equal.6–9  \nCytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have become the mainstay of treatment for appendiceal mucinous neoplasms with peritoneal dissemination.4, 10, 11 Different chemotherapeutic agents have been used in the delivery of HIPEC. The two most common, oxaliplatin and mitomycin C, have been extensively studied.11–15 We have previously performed a phase  \n1 trial of oxaliplatin for HIPEC and found the maximally tolerated dose in a 120-min perfusion to be 200 mg/M2. 12 Retrospective analyses have reached di","cbCaid9Xqv42ITTk","https://ap.wps.com/l/cbCaid9Xqv42ITTk","pdf",540668,"English","# ABSTRACT\n## Background\n## Patients and Methods\n## Results\n## Conclusions\n# PATIENTS AND METHODS","[{\"question\":\"What patient population and HIPEC regimen were studied in this 10-year follow-up trial?\",\"answer\":\"The trial enrolled patients with mucinous appendiceal neoplasms and peritoneal dissemination. HIPEC was delivered for 120 minutes with either oxaliplatin (200 mg/M2) or mitomycin C (40 mg).\"},{\"question\":\"Were long-term efficacies of mitomycin C and oxaliplatin different?\",\"answer\":\"The study concludes that oxaliplatin and mitomycin C have similar long-term efficacy for HIPEC in this clinical setting, with most patients experiencing long-term survival after CRS and HIPEC.\"}]","Ten-Year Outcome of a Randomized Trial: Cytoreduction and HIPEC with Mitomycin C Versus Oxaliplatin for Appendiceal Neoplasm with Peritoneal Dissemination | PDF",1790012090]